NicOx S.A. (Eurolist: COX) today reported that TOPIGEN Pharmaceuticals Inc. has disclosed promising top-line results from its first phase 2 clinical study for TPI-1020, a new chemical entity licensed from NicOx which is a novel respiratory anti-inflammatory. These results showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects, which could be beneficial in TOPIGEN’s target indication of Chronic Obstructive Pulmonary Disease (COPD). TOPIGEN plans to initiate a phase 2 study in patients with COPD during the second half of 2007 (see TOPIGEN’s press release enclosed).
